Atea Pharmaceuticals (AVIR) vs Opus Genetics (IRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Opus Genetics (IRD) has outperformed Atea Pharmaceuticals (AVIR) over the past year, gaining 117.2% versus a gain of 68.7%. Over five years, IRD leads with a +2.8% price change compared with -87.2% for AVIR. Atea Pharmaceuticals is the larger company by market cap ($401.8 million vs $366.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | IRD |
|---|---|---|
| Share price | $5.01 | $4.41 |
| Market cap | $401.83M | $366.89M |
| 1-day change | -1.18% | +0.68% |
| YTD return | +40.34% | +119.40% |
| 1-year return | +68.69% | +117.24% |
| 5-year return | -87.25% | +2.80% |
| EPS (TTM) | $-2.09 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $7.07 |
| 52-week low | $2.87 | $1.70 |
| Distance from 52-week high | -22.33% | -37.62% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +88.02% | +204.08% |
| Average volume | 298.38K | 2.37M |
| Shares outstanding | 80.20M | 83.20M |
| Employees | 55 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed AVIR by 48.6 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
AVIR vs IRD FAQ
Which is bigger, Atea Pharmaceuticals or Opus Genetics?
Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $401.83M compared with $366.89M for Opus Genetics (IRD).
Which stock has performed better over the past year, AVIR or IRD?
IRD returned +117.24% over the past 12 months, compared with +68.69% for AVIR (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Opus Genetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.